Giovanni Monteleone

This inventor holds 23 USPTO granted patents and 11 published patent applications, plus 2 CIPO patents and 3 EPO patents, primarily in Antisense Oligonucleotides. Top assignees: Nogra Pharma Limited, Giuliani International Limited, University of Miami. Active years: 2010-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Giovanni Monteleone. Retrieved from https://idiyas.com/inventor/giovanni-monteleone

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 11)

% Patents Active = 30.4

CIPO Patents = 2 (Patent Applications = 8)

EPO Patents = 3 (Patent Applications = 10)

Average Co-Inventor Count = 1.2

ph-index = 13

Forward Citations = 366(Granted Patents)

Location History:

Rome, IT (2010 - 2018)
Grottaferrata, IT (2016 - 2021)

Company Filing History:

Giuliani International Limited

Giuliani Internaitonal Limited

patent

where one patent can have more than one assignee

Years Active: 2010-2021

Loading Chart...

Areas of Expertise:

SMAD7

Antisense Oligonucleotides

Inflammatory Bowel Disease

Colorectal Cancer

Diabetes Treatment

Pancreatic Islets

Fibrosis Treatment

Colon Carcinogenesis

Therapeutic Methods

Medical Applications

Cancer Therapies

Islet Survival

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11162097 - Methods of treating intestinal fibrosis using SMAD7 inhibition (2021-11-02),

2. 10738309 - Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field (2020-08-11),

3. 10633660 - Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field (2020-04-28),

4. 10473669 - Methods for treating inflammatory bowel disease (2019-11-12),

5. 10443056 - Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation (2019-10-15),

6. 10337004 - Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide (2019-07-02),

7. 10081809 - Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation (2018-09-25),

8. 10036022 - Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field (2018-07-31),

9. 10006029 - Methods of treating colorectal cancer (2018-06-26),

10. 9951334 - Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field (2018-04-24),

11. 9791442 - Methods of monitoring responsiveness to anti-SMAD7 therapy (2017-10-17),

12. 9605264 - Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field (2017-03-28),

13. 9518264 - Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field (2016-12-13),

14. 9382541 - Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field (2016-07-05),

15. 9279126 - Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field (2016-03-08),

Title: Giovanni Monteleone: Innovator in Intestinal Fibrosis Treatment

Introduction

Giovanni Monteleone, based in Grottaferrata, Italy, is an accomplished inventor with a remarkable portfolio of 23 patents. His innovative work primarily focuses on therapies addressing intestinal fibrosis, which is a significant concern in gastrointestinal health.

Latest Patents

Among his latest patents, Monteleone has developed methods for treating intestinal fibrosis using SMAD7 inhibition. This invention details techniques for treating, preventing, or managing intestinal fibrosis by inhibiting SMAD7. It also encompasses methods to monitor treatment effectiveness through the use of a SMAD7 antisense oligonucleotide. In addition, these methods facilitate the regulation of SMAD7 antisense oligonucleotide treatment based on analyses of levels of Transforming Growth Factor-β (TGF-β), α-Smooth Muscle Actin (a-SMA), and phosphorylated Mothers Against Decapentaplegic Homolog 3 (p-SMAD3) levels. Furthermore, his inventions include antisense oligonucleotidic sequences against SMAD7, which are suitably modified for use as therapeutic agents in the medical field, particularly in treating chronic inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.

Career Highlights

Giovanni Monteleone has made significant contributions to the pharmaceutical landscape through his work, including positions at several prominent companies. He has worked with Nogra Pharma Limited and Giuliani International Limited, where he played integral roles in advancing therapeutic innovations.

Collaborations

Throughout his career, Monteleone has collaborated with prominent colleagues in the field. Notable collaborators include Salvatore Bellinvia and Francesca Viti, with whom he has shared ideas and expertise to further the development of groundbreaking medical therapies.

Conclusion

In summary, Giovanni Monteleone stands out as a notable inventor in the field of intestinal health with a strong focus on the potential of SMAD7 inhibition for treating intestinal fibrosis. His numerous patents and collaborations exemplify his commitment to advancing medical treatments and improving patient outcomes.

Profile summary based on public USPTO records.